<rst>
	<header>
		<relations>
			<rel name="antithesis" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="elaboration" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="evidence" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="justify" type="rst"/>
			<rel name="motivation" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="multinuc"/>
			<rel name="restatement" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="solutionhood" type="rst"/>
		</relations>
	</header>
	<body>
		<segment id="1" parent="2" relname="evaluation">But I don't think people are crediting us as one of the best in the world.</segment>
		<segment id="2" parent="21" relname="evaluation">But in the other three, no matter how you see it, we are in the top quartile.</segment>
		<segment id="3" parent="21" relname="elaboration">That combined with firepower and that combined with a good brand name,</segment>
		<segment id="4" parent="5" relname="evaluation">I think if we play the cards right,</segment>
		<segment id="5" >we have dramatic advantage over our competition.</segment>
		<segment id="6" parent="7" relname="circumstance">Unidentified Analyst Okay.</segment>
		<segment id="7" parent="8" relname="circumstance">Albert Bourla If we don't, of course, the same</segment>
		<segment id="8" >-- Unidentified Analyst I want to touch --</segment>
		<segment id="9" parent="8" relname="circumstance">we got about a little bit more than 15 minutes left,</segment>
		<segment id="10" parent="11" relname="concession">so if folks would</segment>
		<segment id="11" >-- I'm going to leave the last five minutes for questions for the audience.</segment>
		<segment id="12" parent="13" relname="circumstance">So if folks in the room would like to think about a question,</segment>
		<segment id="13" >I'll ask you to raise your hand and ask it as we finish in the last five minutes.</segment>
		<segment id="14" parent="15" relname="condition">But before that,</segment>
		<segment id="15" parent="16" relname="elaboration">I'd like to hit if possible a couple of specific therapeutic areas</segment>
		<segment id="16" >and then a couple of industry issues.</segment>
		<segment id="17" parent="18" relname="circumstance">So on therapeutic areas directly,</segment>
		<segment id="18" >one of them is this issue of your presence in immunology.</segment>
		<segment id="19" parent="18" relname="preparation">So there was a lot of effort in Pfizer around the JAK class.</segment>
		<segment id="20" parent="19" relname="circumstance">You have since diversified.</segment>
		<group id="21" type="span" />
	</body>
</rst>
